Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
FRIEDLANDS 10.000-JAHRE-SCHOCK: Der Kupfer-Engpass hat begonnen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
33 Leser
Artikel bewerten:
(0)

Global Pharmacy Benefit Management Market 2017-2021 - Disruption of Key M&A & Growing Focus on Promotional Activities

DUBLIN, Dec. 18, 2017 /PRNewswire/ --

The "Global Pharmacy Benefit Management Market 2017-2021" report has been added to Research and Markets' offering.

Research and Markets Logo

The global pharmacy benefit management market to grow at a CAGR of 6.14% during the period 2017-2021.

Global Pharmacy Benefit Management Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is disruption of key M&A. The market is heavily reliant on key M&A as they can determine whether a new combined entity will emerge and threaten to occupy the larger market share. Key mergers between two mid-sized companies could also propel them to form a combined entity, which would command a greater market share.

According to the report, one driver in the market is increasing global healthcare expenditure. The growing prevalence of generic and chronic diseases and low co-payment or co-insurance costs have resulted in the increase in healthcare expenditures across the world. Healthcare expenditure is the measure of the overall amount spent on healthcare products and services. This also includes personal healthcare such as rehabilitative care, long-term care, and ancillary services. Healthcare is financed through a mix of financing arrangements including government spending and compulsory health insurance as well as voluntary health insurance and private funds such as households' out-of-pocket payments and private corporations.

Further, the report states that one challenge in the market is unclear revenue models. Pharmacy benefit management companies have faced criticism with regards to their revenue models and how they disclose limited information about their revenue sources. The lack of a global regulatory body has been cited in federal courts and senate meetings in the US as the root cause of unfair business practices being prevalent in the market. It has been alleged that the market lacks three essential elements that define a competitive market. They are transparency, choice, and lack of conflicts of interest. These aspects individually or in combination have prevailed in the market and have given rise to PBMs engaging in anticompetitive, deceptive, and fraudulent conduct.

Key vendors

  • Aetna
  • Cigna
  • CVS Health
  • Express Scripts
  • UnitedHealth

Other prominent vendors

  • Anthem
  • Centene
  • China Jo-Jo Drugstore
  • DST Systems
  • Humana
  • Kaiser Permanente
  • Magellan Health
  • McKesson
  • MedImpact
  • OmedaRx
  • Prime Rx Pharmacy
  • Prime Therapeutics
  • Rite Aid
  • RxSolutions
  • Vidalink
  • Walgreens Boots Alliance

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2016
  • Market size and forecast

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: CUSTOMER LANDSCAPE

PART 08: SEGMENTATION BY TYPE OF SERVICE

  • Overview
  • Comparison by type of service
  • Retail/mail-order pharmacy
  • Specialty pharmacy
  • Preferred network pharmacy
  • Other
  • Market opportunity by type of service

PART 09: REGIONAL LANDSCAPE

  • Overview
  • Regional comparison
  • Americas
  • EMEA
  • APAC
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Shift toward multi-tier prescription drug formulary
  • Disruption of key M&A
  • Growing focus on promotional activities

PART 13: VENDOR LANDSCAPE

  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Aetna
  • Cigna
  • CVS Health
  • Express Scripts
  • UnitedHealth
  • Other prominent vendors

PART 15: APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/2c3s7n/global_pharmacy?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

© 2017 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.